I've said it before and I'll say it again, the depth of understanding of biotech on the ASX is that of a muddy puddle.
It seems many investors are trying to value the company like a widget manufacturer. Great buying opportunity for the informed investor...
Ann: Phase 2 trial shows significant improvements in Angelman, page-74
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.86 |
Change
-0.150(1.15%) |
Mkt cap ! $1.646B | |||
| Open | High | Low | Value | Volume |
| $12.80 | $12.90 | $12.69 | $3.006M | 234.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 58 | $12.85 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.86 | 482 | 5 |
View Market Depth
| Last trade - 14.46pm 16/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |